Yue · eLife 2022 · controlled laboratory animal experiment · n=?

TRPV1 drugs alter core body temperature via central projections of primary afferent sensory neurons.

Cited 53 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal and mechanistic study

PubMed 35968676 · doi:10.7554/eLife.80139 · record verified 2026-08-30

What was done

Researchers evaluated the pathways mediating body temperature changes induced by TRPV1 agonists and antagonists in vivo. They selectively eliminated TRPV1 expression in either sensory neurons or vascular smooth muscle cells (vSMCs). They further assessed core temperature responses after selectively lesioning the central projections of TRPV1-positive sensory nerve fibers and after genetically eliminating calcitonin gene-related peptide (CGRP).

What was found

Selective elimination of TRPV1 in sensory neurons abolished both agonist-induced hypothermia and antagonist-induced hyperthermia, whereas deletion in vSMCs had no effect. Lesioning the central projections of TRPV1-positive sensory fibers also prevented drug-induced thermomodulation, while eliminating CGRP did not affect temperature responses. The abstract reports qualitative directions of effect without quantitative metrics, effect sizes, or exact numbers.

Why it matters

Therapeutic development of TRPV1 analgesics has been hindered by severe body temperature side effects. Demonstrating that these side effects stem from sensory input to central thermoregulatory circuits rather than local vascular mechanisms informs the design of next-generation analgesics that avoid central thermomodulatory actions.

Limits

The study is restricted to animal models, so findings require clinical validation in humans. Specific sample sizes, animal species/strains, drug compounds, dosages, and quantitative statistical measures are omitted from the abstract.

Cited by